MedTrace Logo

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

NCT02159859 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2018-10-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.

Conditions

Interventions

DRUG

Ertapenem

Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn

Sponsors & Collaborators

  • Wayne State University

    collaborator OTHER

  • William Beaumont Hospitals

    lead OTHER

Principal Investigators

  • Lama Hsaiky, Pharm.D. · Oakwood Hospital - Dearborn

  • Lama Hsaiky, Pharm.D. · Oakwood Hospital - Dearborn

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
88 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-04-30
Completion
2016-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02159859 on ClinicalTrials.gov